A leap toward regenerating damaged lungs

Lung disease remains one of humanity's toughest medical challenges. Every year, millions die from conditions that slowly rob them of the ability to breathe. Treatments today manage symptoms; none can rebuild the tissue that's been lost. Wouldn't it be ideal if doctors could repair damaged lungs not by transplanting new organs, but by transforming a patient’s own skin cells into fresh lung tissue? That idea, which once sounded like science fiction, has just taken a remarkable step toward reality.

In a paper published in npj Regenerative Medicine, a Japanese research team led by Dr. Makoto Ishii of Nagoya University and Dr. Takanori Asakura of Keio University reports a world-first: they have directly reprogrammed mouse fibroblasts, the connective tissue cells found in skin and other organs, into alveolar epithelial-like cells, the tiny structures that line the air sacs of the lungs.

These lab-grown cells, which the team calls iPULs (induced pulmonary alveolar epithelial-like cells), can not only behave like natural lung cells in a dish but also integrate into injured lung tissue in live mice. The finding opens the door to future therapies for chronic lung diseases such as pulmonary fibrosis and COPD, where scarring or cell loss destroys the lungs' ability to exchange oxygen.

For decades, scientists have dreamed of regenerating lung tissue. Every breath we take depends on delicate, bubble-like structures called alveoli, lined by two cell types: type 1 cells (which handle gas exchange) and type 2 cells (AT2), which act like the lungs' stem cells, repairing tissue and producing surfactant to keep the alveoli open.

In diseases like idiopathic pulmonary fibrosis (IPF), these AT2 cells are damaged or age prematurely, leading to progressive scarring and irreversible loss of lung function. Current treatments can only slow the disease; lung transplants are often the last resort, but they're limited by donor shortages and high risks.

Stem cell therapy has long been seen as a solution, but using induced pluripotent stem cells (iPSCs), the versatile cells created from adult tissues, has proven complex, time-consuming, and sometimes unsafe. iPSCs must be carefully coaxed through multiple developmental stages to become lung cells, a process that can introduce errors or even cancer risks.

That's where the new study takes a bold shortcut. Instead of retracing embryonic development, the researchers asked: what if we could flip a the identity of a cell directly?

This process, called direct reprogramming, uses a handful of “master” genes, transcription factors that tell a cell what to become, to overwrite its existing identity. It's been done before to turn fibroblasts into heart, liver, and nerve cells. But until now, no one had successfully reprogrammed them into alveolar epithelial cells, which are among the most complex and specialized in the body.

The Japanese team began by screening 14 genes known to be important in lung development. After painstaking experiments, they discovered that a combination of just four genes, Nkx2-1, Foxa1, Foxa2, and Gata6, was the magic mix.

When these genes were introduced into mouse fibroblasts and grown in a 3D organoid culture, the cells began to form tiny, spherical clusters that emitted a green glow from a reporter gene linked to surfactant production, a hallmark of functioning alveolar type 2 cells.

Under the microscope, the reprogrammed cells showed all the telltale signs of lung alveolar cells: microvilli on their surface and lamellar bodies inside, the structures that store and secrete surfactant, the soapy substance that keeps air sacs from collapsing.

These iPULs could be expanded for months in culture, even after freezing and thawing, and they expressed the same molecular markers as genuine AT2 cells. When grown in 3D “alveolosphere” organoids, they formed hollow structures resembling miniature lung sacs.

Crucially, when the team transplanted these cells into mice whose lungs had been damaged by a chemical called bleomycin, the iPULs integrated into the alveolar lining. Once there, they even began to differentiate into both AT2 and type 1-like cells, suggesting they could contribute to actual tissue repair.

Even better, the transplanted cells didn't form tumors, a vital safety milestone.

While the achievement is groundbreaking, the work was done in mice, and the team notes that the same method doesn't yet work in human cells. Moreover, only a small percentage of transplanted cells successfully engrafted, and their long-term function remains under study.

Still, the implications are profound. By bypassing stem cells entirely, this approach reduces the risk of tumor formation and simplifies cell preparation, potentially allowing faster, safer therapies. It might also make possible a future in which doctors could reprogram cells directly inside a patient's lungs, a concept known as in vivo reprogramming.

The direct reprogramming method pioneered by the research team represents a radical new strategy. It offers a way to grow lung tissue from a patient's own cells, eliminating the need for donors, immune suppression, or complicated stem cell steps. If adapted for humans, it could change how we treat not only chronic lung diseases but also acute injuries, such as those from infections or toxic exposures.

As we've learned, science is still far from turning this into a therapy you'd see in a hospital. Yet, every great medical leap begins with an experiment like this, a proof that the impossible can be done.

The ability to turn ordinary skin or connective tissue cells into functioning lung cells expands the toolkit of regenerative medicine and, simultaneously, challenges our understanding of what a cell is capable of. In essence, it says that the blueprint for healing is already within us, waiting for the right instructions.

If you want to learn more, read the original article titled "Direct reprogramming of mouse fibroblasts into self-renewable alveolar epithelial-like cells" on npj Regenerative Medicine at http://dx.doi.org/10.1038/s41536-025-00411-4.